View Older Stories View More Recent Stories

Sep 10, 2020 07:30AM KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies
Sep 2, 2020 04:05PM KemPharm to Present at Upcoming September Investor Conferences
Aug 14, 2020 07:30AM KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA
Aug 12, 2020 04:05PM KemPharm Reports Second Quarter 2020 Financial Results
Aug 4, 2020 07:30AM KemPharm to Report Second Quarter 2020 Financial Results
Jul 28, 2020 07:30AM KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484
Jun 18, 2020 08:30AM KemPharm Issues Letter to Shareholders
May 19, 2020 07:32AM KemPharm (KMPH) Receives Day-74 Letter for KP415 NDA, FDA Sets PDUFA Date of March 2, 2021
May 19, 2020 07:30AM KemPharm Receives Day-74 Letter for KP415 NDA
May 12, 2020 04:05PM KemPharm Reports First Quarter 2020 Financial Results
May 6, 2020 04:15PM KemPharm to Report First Quarter 2020 Financial Results
May 4, 2020 08:05AM KemPharm (KMPH) Announces NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA
May 4, 2020 08:00AM NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital
Mar 2, 2020 04:47PM KemPharm (KMPH) Submits KP415 NDA to FDA for the Treatment of ADHD
Mar 2, 2020 04:18PM KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD
Feb 28, 2020 07:30AM KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results
Jan 15, 2020 08:37AM KemPharm (KMPH) Announces Nasdaq Grants its Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement
Jan 15, 2020 08:30AM Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement
Dec 18, 2019 07:15AM KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital
Nov 14, 2019 04:55PM KemPharm Reports Third Quarter 2019 Results
Nov 12, 2019 08:30AM KemPharm to Report Third Quarter 2019 Results
Oct 31, 2019 08:30AM KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019
Oct 22, 2019 04:15PM KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting
Sep 20, 2019 05:00PM KemPharm Provides Updates Regarding its Board of Directors
Sep 17, 2019 08:30AM KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
Sep 5, 2019 07:30AM KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
Sep 4, 2019 08:05AM KemPharm (KMPH) Enters Definitive Collaboration and License Agreement for its ADHD Candidates with Affiliate of Gurnet Point Capital
Sep 4, 2019 08:00AM KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital
Aug 13, 2019 05:00PM KemPharm Reports Second Quarter 2019 Results
May 14, 2019 04:05PM KemPharm Reports First Quarter 2019 Results
Apr 11, 2019 04:21PM KemPharm (KMPH) Reports Completion of KP415 Pre-NDA Meeting with FDA
Apr 11, 2019 04:17PM KemPharm Completes KP415 Pre-NDA Meeting with FDA
Mar 13, 2019 07:36AM KemPharm (KMPH) Provides Update on APADAZ Formulary Adoption
Mar 13, 2019 07:30AM KemPharm Provides Update on APADAZ® Formulary Adoption
Mar 5, 2019 07:30AM KemPharm to Present at Upcoming Investor Conferences
Feb 28, 2019 04:05PM KemPharm Reports Q4 and FY 2018 Results
Feb 21, 2019 04:15PM KemPharm to Report Fourth Quarter and Year End 2018 Results
Jan 29, 2019 07:30AM KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate
Jan 18, 2019 07:30AM KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting
Dec 19, 2018 07:30AM KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio
Dec 12, 2018 07:30AM KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)
Nov 13, 2018 07:30AM KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder
Nov 8, 2018 04:05PM KemPharm, Inc. Reports Third Quarter 2018 Results
Nov 1, 2018 07:30AM KemPharm to Report Third Quarter 2018 Results
Oct 30, 2018 05:23PM KemPharm (KMPH) Enters License Agreement with KVK Tech
Oct 30, 2018 04:05PM KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®
Oct 24, 2018 07:30AM KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting
Oct 23, 2018 07:41AM KemPharm (KMPH) Announces Technology Pact with twoXAR Inc. to Develop Prodrug-Based Therapies for Multiple Indications
Oct 23, 2018 07:30AM KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications
Oct 11, 2018 04:05PM KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape
View More Recent Stories View Older Stories